10x Genomics (TXG) News Today $7.61 -0.36 (-4.53%) As of 12:55 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period 10x Genomics (NASDAQ:TXG) Sets New 12-Month Low - What's Next?10x Genomics (NASDAQ:TXG) Hits New 52-Week Low - Should You Sell?April 4 at 4:04 AM | marketbeat.comVizgen Announces End of Litigation with 10x Genomics and Harvard UniversityApril 3 at 8:00 AM | businesswire.comIQ EQ FUND MANAGEMENT IRELAND Ltd Increases Stock Holdings in 10x Genomics, Inc. (NASDAQ:TXG)IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its holdings in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 160.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 52,787 shares of the company's stock after purchasing an additionMarch 30, 2025 | marketbeat.comWe Think 10x Genomics (NASDAQ:TXG) Can Easily Afford To Drive Business GrowthMarch 27, 2025 | finance.yahoo.com10x Genomics (NASDAQ:TXG) Stock Price Down 5.7% - Time to Sell?10x Genomics (NASDAQ:TXG) Shares Down 5.7% - Here's WhyMarch 26, 2025 | marketbeat.comQuantbot Technologies LP Invests $1.03 Million in 10x Genomics, Inc. (NASDAQ:TXG)Quantbot Technologies LP acquired a new position in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 71,429 shares of the company's stock, valued at approMarch 26, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Trims Position in 10x Genomics, Inc. (NASDAQ:TXG)Charles Schwab Investment Management Inc. lessened its stake in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 17.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 539,666 shares of the company's stock after selling 11March 24, 2025 | marketbeat.com10x Genomics' (TXG) Sell (E+) Rating Reiterated at Weiss RatingsWeiss Ratings restated a "sell (e+)" rating on shares of 10x Genomics in a report on Saturday.March 24, 2025 | marketbeat.comAmundi Reduces Holdings in 10x Genomics, Inc. (NASDAQ:TXG)Amundi reduced its stake in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 98.0% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,988 shares of the company's stock after selling 98,904 sharesMarch 23, 2025 | marketbeat.comPrimecap Management Co. CA Lowers Stock Position in 10x Genomics, Inc. (NASDAQ:TXG)Primecap Management Co. CA trimmed its holdings in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 56.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 127,600 shares of the company's stockMarch 21, 2025 | marketbeat.com10x Genomics: Lower Cost Innovation May Drive A ReboundMarch 20, 2025 | seekingalpha.com10x Genomics, Inc. (NASDAQ:TXG) Short Interest Up 21.6% in February10x Genomics, Inc. (NASDAQ:TXG - Get Free Report) was the target of a significant increase in short interest in February. As of February 28th, there was short interest totalling 13,770,000 shares, an increase of 21.6% from the February 13th total of 11,320,000 shares. Currently, 12.6% of the shares of the company are sold short. Based on an average trading volume of 2,480,000 shares, the short-interest ratio is presently 5.6 days.March 19, 2025 | marketbeat.comBank of New York Mellon Corp Reduces Stock Holdings in 10x Genomics, Inc. (NASDAQ:TXG)Bank of New York Mellon Corp lessened its stake in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 13.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 290,031 shares of the company's stock after selling 45,337 sharMarch 19, 2025 | marketbeat.comNikko Asset Management Americas Inc. Reduces Stock Position in 10x Genomics, Inc. (NASDAQ:TXG)Nikko Asset Management Americas Inc. lessened its holdings in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 10.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,713,484 shares of the company's stock after sellinMarch 18, 2025 | marketbeat.comCounterpoint Mutual Funds LLC Invests $742,000 in 10x Genomics, Inc. (NASDAQ:TXG)Counterpoint Mutual Funds LLC acquired a new stake in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 51,658 shares of the company's stock, valued at approximately $742,March 18, 2025 | marketbeat.com10x Genomics, Inc. (NASDAQ:TXG) Receives Average Rating of "Hold" from Analysts10x Genomics, Inc. (NASDAQ:TXG - Get Free Report) has been assigned an average rating of "Hold" from the seventeen brokerages that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and seveMarch 16, 2025 | marketbeat.comWealthfront Advisers LLC Takes Position in 10x Genomics, Inc. (NASDAQ:TXG)Wealthfront Advisers LLC acquired a new stake in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 332,210 shares of the coMarch 14, 2025 | marketbeat.com2 Reasons to Sell TXG and 1 Stock to Buy InsteadMarch 11, 2025 | finance.yahoo.comEdgestream Partners L.P. Invests $2.74 Million in 10x Genomics, Inc. (NASDAQ:TXG)Edgestream Partners L.P. bought a new position in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 190,714 shares of the company's stock, valued at approximately $2,739,000. Edgestream PartnMarch 10, 2025 | marketbeat.com10x Genomics (NASDAQ:TXG) Trading Up 4.9% - Time to Buy?10x Genomics (NASDAQ:TXG) Trading Up 4.9% - Still a Buy?March 5, 2025 | marketbeat.com10x Genomics (NASDAQ:TXG) Price Target Lowered to $15.00 at CitigroupCitigroup decreased their target price on shares of 10x Genomics from $20.00 to $15.00 and set a "buy" rating for the company in a report on Tuesday.March 5, 2025 | marketbeat.com10x Genomics secures injunction against Parse Biosciences’ planned ATAC productsMarch 4, 2025 | markets.businessinsider.com10x Genomics gets injunction against Parse Biosciences' ATAC ProductsMarch 4, 2025 | msn.com10x Genomics price target lowered to $15 from $20 at CitiMarch 4, 2025 | markets.businessinsider.comShort Interest in 10x Genomics, Inc. (NASDAQ:TXG) Expands By 34.4%10x Genomics, Inc. (NASDAQ:TXG - Get Free Report) was the target of a significant increase in short interest during the month of February. As of February 15th, there was short interest totalling 11,320,000 shares, an increase of 34.4% from the January 31st total of 8,420,000 shares. Based on an average trading volume of 2,280,000 shares, the short-interest ratio is presently 5.0 days.March 4, 2025 | marketbeat.com10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC ProductsMarch 3, 2025 | prnewswire.com10x Genomics (NASDAQ:TXG) Hits New 52-Week Low - Time to Sell?10x Genomics (NASDAQ:TXG) Sets New 1-Year Low - Should You Sell?March 3, 2025 | marketbeat.comSVB Wealth LLC Acquires Shares of 522,609 10x Genomics, Inc. (NASDAQ:TXG)SVB Wealth LLC acquired a new stake in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 522,609 shares of the company's stock, valued at approximately $7,505,000. SVB WealthMarch 1, 2025 | marketbeat.com10x Genomics, Inc. (NASDAQ:TXG) Insider Benjamin J. Hindson Sells 4,573 Shares10x Genomics, Inc. (NASDAQ:TXG - Get Free Report) insider Benjamin J. Hindson sold 4,573 shares of the business's stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $11.07, for a total transaction of $50,623.11. Following the completion of the transaction, the insider now owns 335,324 shares in the company, valued at approximately $3,712,036.68. This trade represents a 1.35 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.February 27, 2025 | marketbeat.comSerge Saxonov Sells 5,092 Shares of 10x Genomics, Inc. (NASDAQ:TXG) Stock10x Genomics, Inc. (NASDAQ:TXG - Get Free Report) CEO Serge Saxonov sold 5,092 shares of the firm's stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $11.07, for a total transaction of $56,368.44. Following the completion of the sale, the chief executive officer now owns 879,482 shares of the company's stock, valued at $9,735,865.74. This trade represents a 0.58 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.February 27, 2025 | marketbeat.comInsider Selling: 10x Genomics, Inc. (NASDAQ:TXG) Insider Sells 4,573 Shares of StockFebruary 27, 2025 | insidertrades.comNew York State Common Retirement Fund Sells 39,010 Shares of 10x Genomics, Inc. (NASDAQ:TXG)New York State Common Retirement Fund lowered its holdings in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 7.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 476,338 shares of the companyFebruary 27, 2025 | marketbeat.comAlan Mateo Buys 40,000 Shares of 10x Genomics, Inc. (NASDAQ:TXG) Stock10x Genomics, Inc. (NASDAQ:TXG - Get Free Report) Director Alan Mateo acquired 40,000 shares of 10x Genomics stock in a transaction on Friday, February 21st. The shares were bought at an average price of $11.14 per share, for a total transaction of $445,600.00. Following the purchase, the director now owns 61,691 shares of the company's stock, valued at $687,237.74. This represents a 184.41 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.February 26, 2025 | marketbeat.comARK Investment Management LLC Acquires 1,193,712 Shares of 10x Genomics, Inc. (NASDAQ:TXG)ARK Investment Management LLC boosted its holdings in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 11.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 11,944,057 shares of the company's stock after purchasing an additioFebruary 26, 2025 | marketbeat.com10x Genomics, Inc. (NASDAQ:TXG) Director Alan Mateo Buys 40,000 SharesFebruary 26, 2025 | insidertrades.com10x Genomics (NASDAQ:TXG) Hits New 52-Week Low - Should You Sell?10x Genomics (NASDAQ:TXG) Hits New 12-Month Low - Here's WhyFebruary 24, 2025 | marketbeat.comING Groep NV Acquires Shares of 75,400 10x Genomics, Inc. (NASDAQ:TXG)ING Groep NV bought a new position in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 75,400 shares of the company's stock, valued at approximately $1,083,000. ING Groep NV oFebruary 24, 2025 | marketbeat.comIeq Capital LLC Buys 50,722 Shares of 10x Genomics, Inc. (NASDAQ:TXG)Ieq Capital LLC lifted its position in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 47.2% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 158,112 shares of the company's stock after buying an additional 50,7February 24, 2025 | marketbeat.com10x Genomics unveils roadmap at AGBT general meetingFebruary 23, 2025 | markets.businessinsider.com10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, Advancing Leadership in Large-Scale Single Cell and Spatial AnalysisFebruary 23, 2025 | prnewswire.comAlberta Investment Management Corp Makes New $3.21 Million Investment in 10x Genomics, Inc. (NASDAQ:TXG)Alberta Investment Management Corp acquired a new stake in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 223,280 shares of the company's stock, valued at apFebruary 21, 2025 | marketbeat.comWeiss Ratings Reiterates Sell (E+) Rating for 10x Genomics (NASDAQ:TXG)Weiss Ratings reaffirmed a "sell (e+)" rating on shares of 10x Genomics in a report on Wednesday.February 20, 2025 | marketbeat.com10x Genomics, Inc. (NASDAQ:TXG) Given Consensus Recommendation of "Hold" by BrokeragesShares of 10x Genomics, Inc. (NASDAQ:TXG - Get Free Report) have been given an average recommendation of "Hold" by the seventeen brokerages that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and seven havFebruary 19, 2025 | marketbeat.com10x Genomics to Participate in the 45th Annual TD Cowen Health Care ConferenceFebruary 18, 2025 | prnewswire.comWilliam Blair Estimates 10x Genomics Q3 Earnings10x Genomics, Inc. (NASDAQ:TXG - Free Report) - Research analysts at William Blair issued their Q3 2025 earnings per share (EPS) estimates for 10x Genomics in a research report issued to clients and investors on Thursday, February 13th. William Blair analyst M. Larew anticipates that the companyFebruary 17, 2025 | marketbeat.comLeerink Partnrs Lowers Earnings Estimates for 10x Genomics10x Genomics, Inc. (NASDAQ:TXG - Free Report) - Leerink Partnrs dropped their Q1 2025 earnings per share estimates for 10x Genomics in a research report issued to clients and investors on Thursday, February 13th. Leerink Partnrs analyst P. Souda now anticipates that the company will post earningsFebruary 17, 2025 | marketbeat.com10x Genomics (NASDAQ:TXG) Shares Up 8.3% - Here's Why10x Genomics (NASDAQ:TXG) Stock Price Up 8.3% - Time to Buy?February 15, 2025 | marketbeat.com10x Genomics (NASDAQ:TXG) Price Target Cut to $26.00 by Analysts at Morgan StanleyMorgan Stanley reduced their price target on shares of 10x Genomics from $28.00 to $26.00 and set an "overweight" rating on the stock in a research report on Friday.February 15, 2025 | marketbeat.comLeerink Partnrs Forecasts 10x Genomics Q1 Earnings10x Genomics, Inc. (NASDAQ:TXG - Free Report) - Leerink Partnrs issued their Q1 2026 EPS estimates for 10x Genomics in a research report issued on Thursday, February 13th. Leerink Partnrs analyst P. Souda anticipates that the company will post earnings of ($0.35) per share for the quarter. LeerinFebruary 15, 2025 | marketbeat.com10x Genomics (NASDAQ:TXG) Lowered to "Hold" Rating by Leerink PartnrsLeerink Partnrs cut 10x Genomics from a "strong-buy" rating to a "hold" rating in a report on Thursday.February 15, 2025 | marketbeat.com Remove Ads Get 10x Genomics News Delivered to You Automatically Sign up to receive the latest news and ratings for TXG and its competitors with MarketBeat's FREE daily newsletter. Email Address TXG Media Mentions By Week TXG Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TXG News Sentiment▼0.800.61▲Average Medical News Sentiment TXG News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TXG Articles This Week▼36▲TXG Articles Average Week Remove Ads Get 10x Genomics News Delivered to You Automatically Sign up to receive the latest news and ratings for TXG and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Sensata Technologies News Mirion Technologies News Camtek News Transcat News Cytek Biosciences News Senseonics News Standard BioTools News Allient News EyePoint Pharmaceuticals News Quanterix News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TXG) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredRUTHLESS Musk Move >> coming June 1?Elon Musk has made headlines with everything from mass layoffs to political drama — but his next move could sh...Paradigm Press | SponsoredThe bigger story behind the recent market pullbackNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 10x Genomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 10x Genomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
